The purpose of our study was to determine whether SGLT2 inhibitors can improve pulmonary vascular remodelling by inhibiting NLRP3 inflammasome activation and the potential benefit of combination therapy with dapagliflozin and sildenafil in monocrotaline (MCT)-treated rats, a widely used surrogate model of PAH. This evidence concerns the gene NLRP3 and pulmonary arterial hypertension.